The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines ...

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

The S&P 500 fell 0.3% on Tuesday, Dec. 10, as the cooldown from last week's record-setting rally continued ahead of key ...

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

CEO Stéphane Bancel said that he plans to address any partisan hurdles with the incoming Trump administration’s vaccine and ...

The S&P 500 has hit record levels this year and many stocks have generated fantastic returns for investors. But there's been ...

Bullish option flow detected in Moderna (MRNA) with 29,554 calls trading, 1.7x expected, and implied vol increasing almost 2 points to 71.71%.

The murder of UnitedHealthcare chief executive Brian Thompson in Manhattan on Wednesday has raised questions about security ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell today? The S&P 500 has hit record levels this year and many stocks have ...

Shares of Moderna Inc. MRNA slid 2.23% to $41.63 Wednesday, on what proved to be an all-around great trading session for the ...